Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues

American Journal of Cardiology

Volumn 91, Issue 6 SUPPL. 1, 2003, Pages 39-44

  Wolbrette, Deborah L ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANDROGEN; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; DRONEDARONE; POTASSIUM; SOTALOL; TEDISAMIL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG FORMULATION; DRUG TOLERANCE; DRUG USE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART PROARRHYTHMIA; HORMONE DETERMINATION; HUMAN; PATIENT CARE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PUBERTY; QT INTERVAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TORSADE DES POINTES;

EID: 0037456807     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03378-7     Document Type: Review

References (38)

1. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population based cohort the Framingham Heart Study. JAMA. 271:1994;840-844.
2. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmol R., Hart R.G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 155:1995;469-473.
3. Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Epidemiologic features of chronic atrial fibrillation the Framingham Study. N Engl J Med. 306:1982;1018-1022.
4. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death the Framingham Heart Study. Circulation. 98:1998;946-952.
5. Cabin H.S., Clubb S., Hall C., Perlmutter R.A., Feinstein A.R. Risk for systemic embolization of atrial fibrillation without stenosis. Am J Cardiol. 65:1990;1112-1116.
6. Hnatkova K., Walstare J.E.P., Murgatroyd F.D. Age and gender influences on rate and duration of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 21:1998;2455-2458.
7. Suttorp M.J., Kingma H., Koomen E.M., Hof A.V., Tyssen J.E., Lie K.I. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol. 71:1993;710-713.
8. Middlekauff H.R., Stevenson W.G., Stevenson L.W. Prognostic significance of atrial fibrillation in advanced heart failure a study of 390 patients. Circulation. 84:1991;40-48.
9. Podrid P.J., Lampert S., Graboys T.B., Blatt C.M., Lown B. Aggravation of arrhythmia by antiarrhythmic drugs incidence and predictors. Am J Cardiol. 59:1987;38E-44E.
10. Wolbrette D., Naccarelli G., Curtis A., Lehmann M., Kadish A. Gender differences in arrhythmias. Clin Cardiol. 25:2002;49-56.
11. Lehmann M.H., Timothy K.W., Frankovich D., Fromm B.S., Keating M., Locati E.H., Taggart R.T., Towbin J.A., Moss A.J., Schwarts P.J., Vincent G.M. Age-gender influence on the rate-corrected QT interval and the QT heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol. 29:1997;93-99.
12. Locati E.H., Zareba W., Moss A.J., Schwartz P.J., Vincent G.M., Lehmann M.H., Towbin J.A., Priori S.G., Napolitano C., Robinson J.L., et al. Age and sex related differences in clinical manifestations in patients with congenital long-QT syndrome findings from the International LQTS Registry. Circulation. 97:1998;2237-2244.
13. Lehmann M.H., Hardy S., Archibald D., Quart B., MacNeil D.J. Sex difference in risk of torsades de pointes with d,l-sotalol. Circulation. 94:1996;2534-2541.
14. Kuhlkamp V., Mermi J., Mervis C., Seipel L. Efficacy and proarrhythmias with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. J Cardiovasc Pharmacol. 29:1997;373-381.
15. Lehmann M.H., Hardy S., Archibald D., MacNeil D.J. JTc prolongation with d,l-sotalol in women versus men. Am J Cardiol. 83:1999;354-359.
16. Pratt C.M., Camm A.J., Cooper W., Friedman P.L., MacNeil D.J., Moulton K.M., Pitt B., Schwartz P.J., Veltri E.P., Waldo A.L. Mortality in the Survival With ORal D-sotalol (SWORD) trial why did patients die? Am J Cardiol. 81:1998;869-876.
17. Torp-Pedersen C., Møller M., Bloch-Thomsen P.E., Køber L., Sandøe E., Egstrup K., Agner E., Carlsen J., Videbalk J., Marchant B., Camm A.J. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 341:1999;857-865.
18. Karam R., Marcello S., Brooks R.R., Corey A.E., Moore A. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol. 81:1998;40D-46D.
19. Page R.L., Connolly S.J., Wilkinson W.E., Marcello S.R., Schnell D.J., Pritchett E.L.C. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia efficacy and dose-response. Am Heart J. 143:2002;643-649.
20. Makkar R.R., Fromm B.S., Steinman R.T., Meissmer M.D., Lehmann M.H. Female gender as a risk factor of torsades de pointes associated with cardiovascular drugs. JAMA. 270:1993;2590-2597.
21. Hohnlosser S.H., Singh B.N. Proarrhythmia with class III antiarrhythmic drugs definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol. 6:1995;920-936.
22. Sager P.T. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol. 15:2000;41-53.
23. Priori S.G., Diehl L., Schwartz P.J. Torsades de pointes. Podrid P.J., Kowey P.R. Cardiac Arrhythmia Mechanisms, Diagnosis, and Management. 1995;951-963 Williams and Wilkins, Baltimore.
24. Nattel S. Class III drugs: amiodarone, bretylium, ibutilide, and sotalol. In: Zipes DP, Jalife J. Cardiac Electrophysiology: From Cell to Bedside, 3rd ed. Philadelphia: WB Saunders, 2000:921-932.
25. Reiffel J.A. Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. Am Heart J. 135:1998;551-556.
26. Fuster V., Ryden L.E., Asinger R.W., Cannon D.S., Crijns H.J., Frye R.L., Halperin J.L., Kay G.N., Klein W.W., Levy S., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 104:2001;2118-2150.
27. Eckardt L., Haverkamp W., Breithardt G. Antiarrhythmic therapy in heart failure. Heart Failure Monitor. 2:2002;110-119.
28. Han W, Chartier D, Li D, Nattel S. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation 2001;104:2095-2100.
29. DaCosta A., Chalvidan T., Belounas A., Messier M., Viallet M., Mansour H., Lamaison D., Djiane P., Isaaz K. Predictive factors of ventricular fibrillation triggered by pause-dependent torsades de pointes associated with acquired long QT interval role of QT dispersion and left ventricular function. J Cardiovasc Electrophysiol. 11:2000;990-997.
30. Roden D.M. Taking the "idio" out of "idio-syncratic:" predicting torsades de pointes. Pacing Clin Electrophysiol. 21:1998;1029-1034.
31. Priori S.G., Napolitano C., Schwartz P.J. Low penetrance in the long-QT syndrome. Circulation. 99:1999;529-533.
32. Napolitano C., Schwartz P.J., Brown A.M. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol. 11:2000;691-696.
33. Kubota T., Shimizu W., Kamakura S., Horie M. Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4-S5 linker of KCNQ1. J Cardiovasc Electrophysiol. 11:2000;1048-1054.
34. Reiffel J.A. Issues in the use of generic antiarrhythmic drugs. Curr Opin Cardiol. 16:2001;23-29.
35. Reiffel J.A., Kowey P.R. Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol. 85:2000;1151-1153.
36. Reiffel J.A. Inpatient versus outpatient antiarrhythmic drug initiation safety and cost-effectiveness issues. Curr Opin Cardiol. 15:2000;7-11.
37. Thibault B., Nattel S. Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting protagonist. J Cardiovasc Electrophysiol. 10:1999;472-481.
38. Chung M.K., Schweikert R.A., Wilkoff B.L., Niebauer M.J., Pinski S.L., Trohman R.G., Kidwell G.A., Jaeger F.J., Morant V.A., Miller D.P., Tchou P.J. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol. 32:1998;169-176.